DEFA14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

DEF 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SCHEDULE 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

10-Q - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

PRE 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL. The first candidate developed using RTNova is a vaccinia virus (virotherapy) that is engineered to be tumor selective and produced in an enveloped form that allows the virus to surv

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi's newly appointed Chief Medical Officer, Consultant and Advisor, Guy Travis Clifton, MD, who will share insight into the company's groundbreaking stem cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Dr. Clifton will be joined by Calidi's CFO Andrew Jackson. Dr. Clifto

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast cancer, head & neck cancer and soft tissue sarcoma. The IND application included preclinical data demonstrating the potential of CLD-201 to evade viral inactivation by the patient's immune system and effecti

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. "With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors, Dr. Clifton's oncology and advisory experience will be invaluable to us and our goal to advance our stem cell-based and enveloped virus platforms through the clinic and to patients in need," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biothera

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced registered direct offering, with a single institutional investor, for the issuance and sale of 3,325,000 shares of the Company's common stock, and pre-funded warrants to purchase up to 2,728,000 shares of Common Stock. In a concurrent private placement, the Company issued and sold to the investor Series G common warrants to purchase up to an aggregate of 6,053,000 shares common stock. The combined offering price for each shar

Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with a single institutional investor for the purchase and sale of 3,325,000 shares of the Company's common stock at a per share purchase price of $0.65, and at the election of the investor, in lieu of the common stock, pre-funded warrants to purchase up to 2,728,000 shares of Common Stock at a price of $0.649 per pre-funded warrant, which represents the per share offering price for the common stock

H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. "With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors, Dr. Clifton's oncology and advisory experience will be invaluable to us and our goal to advance our stem cell-based and enveloped virus platforms through the clinic and to patients in need," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biothera

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board Received a new U.S. patent for the company's novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccin

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. This addition increases the board's membership to eight. Dr. Gilbert most recently served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024. Under Dr. Gilbert's leadership, his team of laboratory and clinical investigators conducted groundbreaking research that advanced science in the brain tumor field. He developed robust clinical tria

Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company's Board of Directors, effective July 1, 2024. "Dr. Peoples is a highly esteemed figure in the field of cancer immunotherapy, bringing decades of experience in cancer vaccine development and clinical research to our Board," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "Dr. Peoples' pioneering work in cancer immunotherapy and his extensive experience in both clinical and military settings will be invaluable as we advance our portfolio

City of Hope, a leader in cancer research and treatment, was awarded $5.3 million from California Institute for Regenerative Medicine (CIRM) to develop a treatment for metastatic ovarian cancer using Calidi's licensed lead asset, NeuroNova (CLD-101) Announced novel systemic enveloped oncolytic virotherapy platform, RTNova, designed to target diverse tumor types Strengthened team with the appointment of three new members to Scientific and Medical Advisory Board and one member to Board of Directors Issued new U.S. patent covering novel SuperNova (CLD-201) technology platform Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a ne

Antonio Chiocca, M.D., Ph.D., Chair, Department of Neurosurgery at Brigham and Women's Hospital, Co-Director, Institute for the Neurosciences, and Professor of Neurosurgery at Harvard Medical School David T. Curiel, M.D., Ph.D., Professor of Radiation Oncology at the Washington University School of Medicine Burt L. Nabors, M.D., Professor, Vice Chair for Research, and Division Director of Neuro-Oncology at the University of Alabama at Birmingham Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. The

Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company's Board of Directors effective January 1, 2024. The company also announced the resignation of Director Alfonso Zulueta effective November 29, 2023 and the resignation of Director Tom Vecchiolla effective January 1, 2024. "David LaPré brings a wealth of pharmaceutical industry experience, expertise in solving problems unique to this industry, and a solid understanding of the factors that drive shareholder value. His past experiences will help Calidi move forward as a company, advancing our por